Table 3

Adherence data for osteoporosis medications

ReferenceMedicationPopulation (mean age)Compliance, mean MPR
Abrahamsen29Alendronate58 674 (n/a)<5 years5 to 10 years>10 years
EtidronateAlendronate (92%)Alendronate (84%)Alendronate (76%)
IbandronateEtidronate (92%)Etidronate (89%)Etidronate (88%)
RisedronateIbandronate (81%)Ibandronate (75%)Ibandronate (70%)
ClodronateRisedronate (91%)Risedronate (80%)Risedronate (75%)
Blouin et al20Alendronate15 027 (76.6)69.7%±34.8%
Risedronate
Briesacher et al32Alendronate, risedronate17 988 (61.4)At 1 year,At 2 years,At 3 years,
42.9% (MPR ≥80%)34.5% (MPR ≥80%)30.6% (MPR ≥80%)
12.6% (MPR 60% to 79%)10% (MPR 60% to 79%)10% (MPR 60% to 79%)
10.4% (MPR 40% to 59%)7.7% (MPR 40% to 59%)7.2% (MPR 40% to 59%)
13.8% (MPR 20% to 39%)8.2% (MPR 20% to 39%)7.8% (MPR 20% to 39%)
20.4% (MPR <20%)38.7% (MPR <20%)44.2% (MPR <20%)
Briesacher et al33Alendronate, ibandronate, risedronate61 125 (62.1)At 1 year (monthly medication),At 1 year (weekly medications)At 1 year (daily medication)
49% (MPR≥80%)49% (MPR ≥80%)23% (MPR ≥80%)
11% (MPR 60% to 79%), 11% (MPR 40% to 59%), 13% (MPR 20% to 39%)14% (MPR 60% to 79%)8% (MPR 60% to 79%)
16% (MPR <20%)9% (MPR 40% to 59%)11% (MPR 40% to 59%)
14% (MPR 20% to 39%)16% (MPR 20% to 39%)
14% (MPR <20%)42% (MPR <20%)
Burden et al35Alendronate, etidronate, risedronate337 329 (75.7)70%*
Cadarette et al21Alendronate, risedronate20 205 (79)49.8% (PDC ≥80%); 14.5% (PDC 51% to 79%); 35.7% (PDC ≤50%)
Cheen et al36Alendronate, risedronate798 (68.5)78.90%
Cheng et al23Alendronate1745 (68.1)At 1 year; 61.9%At 2 years, 47.9% (MPR ≥80%)
(MPR >80%)
Colombo and Montecucco37Generic alendronate, branded alendronate20 711 (73)69% to 74%
Copher et al38Alendronate, ibandronate, risedronate1587 (62.3)48.70% (95% CI 46.2 to 51.2)
Cotté et al39Alendronate, risedronate2990 (69.9)79.4% (95% CI 78.2 to 80.5) (weekly medications)
Ibandronate84.5% (95% CI 83.1 to 85.9) (monthly ibandronate)
Cramer et al40Alendronate, risedronate, ibandronate2741 (n/a)60.60%
Cramer et al41Alendronate, risedronate2741(73)64%
Curtis et al42Alendronate, risedronate1158 (53)73%
Curtis et al43Alendronate, risedronate25 446 (n/a)At 2 years,At 3 years,
Achieved MPR >80% = 29.4%Achieved MPR >80% = 27.2%
Achieved MPR <50% = 34.9%Achieved MPR <50% = 39.4%
Curtis et al45Alendronate101 038 (n/a)Achieving MPR >80% = 44%
Ibandronate, risedronate
Devine et al46Alendronate, ibandronate, risedronate22 363 (n/a)62%
Devold et al47Alendronate7610 (66.6)Achieving MPR ≥80% = 45.5%
Downey et al24Alendronate, risedronate10 566 (66.4)60.7% (alendronate)
58.4% (risedronate)
Dugard et al48Not stated254 (76.7)At 1 year,At 3 years,At 5 years, achieving MPR ≥80% = 23%
Achieving MPR ≥80% = 44%Achieving MPR ≥80% = 42%
Feldstein et al50Alendronate, ibandronate, risedronate1829 (72)60%
Gold et al52Ibandronate, risedronate234 862 (n/a)83.3% (risedronate)79% (risedronate)
78.5% (ibandronate)
Gold et al53Ibandronate, risedronate263 383 (66.21)74.68% (ibandronate)
80.15% (risedronate)
Hadji et al55Alendronate, clodronate, etidronate, risedronate4147 (n/a)Achieving MPR ≥80% = 66.3%
Achieving MPR <80% = 22.7%
Halpern et al26Alendronate, ibandronate, risedronate21 655 (63.3)At 6 months,At 18 months,
76% (commercially insured)59% (commercially insured)
68% (Medicare advantage)53% (Medicare advantage)
Hansen et al57Alendronate198 (71)At 12 months,At 2 years,
Achieving MPR ≥80% = 59%Achieving MPR ≥80% = 54%
Hoer et al59Alendronate, etidronate, risedronate4451(n/a)At 6 months,At 1 year,
Achieving MPR ≥80% = 58.6%Achieving MPR ≥80% = 46.25%
Kishimoto and Machara64Not stated12 230 (62)At 1 year,At 5 years,
38.6% (daily)20.8% (daily)
70.6% (weekly)60.9% (weekly)
77.7% (monthly)
LeBlanc et al67Not stated14 674 (71)94%
Lin et al69Alendronate8936 (74)60.20%
Lo et al70Alendronate13 455 (68.8)93%
Martin et al71Alendronate, ibandronate, risedronate45 939 (59.6)At 1 year,At 2 years,At 3 years,
58% (alendronate)48% (alendronate)42% (alendronate)
58% (ibandronate)50% (ibandronate)46% (ibandronate)
57% (isedronate)47% (risedronate)43% (risedronate)
Modi et al75Alendronate, ibandronate, risedronate37 886 (74.1)Achieving MPR ≥80% = 31.7%
Netelenbos et al76Alendronate105 50691%
−69.2
Olsen et al77Alendronate, etidronate47 176 (70.3)Achieving MPR <50% = 28.4%
Achieving MPR 50% to 79% = 11.8%
Achieving MPR ≥80% = 59.8%
Penning-van Beest et al81Alendronate, risedronate8822 (69.4)At 3 months,At 6 months, achieving MPR ≥80%At 1 year,
Achieving an MPR ≥80%Daily = 60.3%Achieving MPR ≥80%,
Daily=72.8%Weekly = 70.8%Daily = 50.2%
Weekly=80.0%Weekly = 64.3%
Penning-van Beest et al82Alendronate, risedronate8822 (n/a)Achieving MPR ≥80% = 58%
Rabenda et al83Alendronate54 807 (n/a)64.70%
Recker et al84Alendronate, risedronate211 319 (n/a)54% (daily regimen)
65% (weekly regimen)
Richards et al86Alendronate, risedronate573 (68.7)69%
Sampalis et al90Alendronate, ibandronate, risedronate636 114 (72)72%
Siris et al93Alendronate, risedronate35 357 (65.3)Achieving MPR ≥80% = 43%
Siris et al94Alendronate, ibandronate, risedronate460 584 (63.6)53.50%
Soong et al95Alendronate32 604 (72.44)At 1 month,At 2 months,At 1 year,
Achieving MPR ≥80% = 87.6%Achieving MPR ≥80% = 61.8%Achieving MPR ≥80% = 28.2%
Sunyecz et al97Alendronate, risedronate32 944 (64.3)55%
Tafaro et al98Alendronate, clodronate, ibandronate, risedronate6390 (n/a)53% (daily regimen)
70% (weekly regimen)
Wang et al101Alendronate, ibandronate, risedronate522 287 (n/a)Achieving MPR <33% = 41.1%
Achieving MPR 34% to 65% = 21.5%
Achieving MPR >66% = 37.3%
Weycker et al104Alendronate, ibandronate, risedronate644 (65.9)57%
Yeaw et al105Alendronate10 268 (56.9)*60%
Ibandronate
Yood et al106Alendronate, etidronate176 (63.3)70.70%
Ziller et al108Alendronate268 568 (63.3)33% (alendronate 10 mg)
57% (alendronate 70 mg)
  • *Mean Proportion of Days Covered (PDC).

  • MPR, medication possession ratio.